Trial Profile

A Phase I clinical trial of LY03017

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Jan 2026 New trial record
24 Nov 2025 According to a Luye Pharma media release, the company received clearance of an IND application from the U.S. Food and Drug Administration (FDA) to initiate clinical trials in the United States. drug is intended to treat Alzheimer's disease psychosis (ADP), Parkinson's disease psychosis (PDP), and the negative symptoms of schizophrenia. FDA has exempted the single ascending dose trial in the Phase I clinical trial of LY03017, and the drug can directly proceed to the multiple ascending dose (MAD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com